DZ2679A1 - Forme hydratée nouvelle d'un dérivé de thiazolidinedione procédé pour sa préparation et composition pharmaceutique la contenant. - Google Patents

Forme hydratée nouvelle d'un dérivé de thiazolidinedione procédé pour sa préparation et composition pharmaceutique la contenant.

Info

Publication number
DZ2679A1
DZ2679A1 DZ980289A DZ980289A DZ2679A1 DZ 2679 A1 DZ2679 A1 DZ 2679A1 DZ 980289 A DZ980289 A DZ 980289A DZ 980289 A DZ980289 A DZ 980289A DZ 2679 A1 DZ2679 A1 DZ 2679A1
Authority
DZ
Algeria
Prior art keywords
preparation
pharmaceutical composition
composition containing
hydrated form
thiazolidinedione derivative
Prior art date
Application number
DZ980289A
Other languages
English (en)
French (fr)
Inventor
Bernadette Marie Choudary
Michael John Sasse
Lan Robert Lynch
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ2679A1 publication Critical patent/DZ2679A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DZ980289A 1997-12-16 1998-12-15 Forme hydratée nouvelle d'un dérivé de thiazolidinedione procédé pour sa préparation et composition pharmaceutique la contenant. DZ2679A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726563.1A GB9726563D0 (en) 1997-12-16 1997-12-16 Novel pharmaceutical

Publications (1)

Publication Number Publication Date
DZ2679A1 true DZ2679A1 (fr) 2003-03-29

Family

ID=10823691

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980289A DZ2679A1 (fr) 1997-12-16 1998-12-15 Forme hydratée nouvelle d'un dérivé de thiazolidinedione procédé pour sa préparation et composition pharmaceutique la contenant.

Country Status (37)

Country Link
US (4) US20020133016A1 (cs)
EP (1) EP1042321A1 (cs)
JP (1) JP2002508371A (cs)
KR (1) KR100549141B1 (cs)
CN (3) CN1285831A (cs)
AP (1) AP1363A (cs)
AR (2) AR016161A1 (cs)
AU (2) AU2272299A (cs)
BG (1) BG64850B1 (cs)
BR (1) BR9813598A (cs)
CA (1) CA2314967A1 (cs)
CO (1) CO4990943A1 (cs)
CZ (1) CZ300081B6 (cs)
DZ (1) DZ2679A1 (cs)
EA (1) EA002833B1 (cs)
EG (1) EG22250A (cs)
GB (1) GB9726563D0 (cs)
HR (1) HRP20000404A2 (cs)
HU (1) HUP0102292A3 (cs)
ID (1) ID24714A (cs)
IL (2) IL136425A (cs)
MA (1) MA26581A1 (cs)
MY (1) MY128573A (cs)
NO (1) NO317255B1 (cs)
NZ (1) NZ504703A (cs)
OA (1) OA11900A (cs)
PE (1) PE20000125A1 (cs)
PL (1) PL341213A1 (cs)
RS (1) RS50080B (cs)
SA (1) SA99200200B1 (cs)
SK (1) SK286422B6 (cs)
TR (2) TR200001793T2 (cs)
TW (1) TW487709B (cs)
UA (1) UA66821C2 (cs)
UY (2) UY25309A1 (cs)
WO (1) WO1999031093A1 (cs)
ZA (1) ZA9811504B (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
AR023561A1 (es) * 1999-04-23 2002-09-04 Smithkline Beecham Corp Una forma polimorfica del acido maleico de un derivado de tiazolidin-2, 4 diona, una composicion farmaceutica y el uso de dicho polimorfo para lafabricacion de un medicamento
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
HRP20010773B1 (en) 1999-04-23 2005-06-30 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
CZ20013801A3 (cs) * 1999-04-23 2002-07-17 Smithkline Beecham Plc Nový léčivý přípravek
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
EP1468997A3 (en) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
US20050163837A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
CA2426117A1 (en) 2000-09-26 2002-04-04 Dr. Reddy's Laboratories Limited Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation

Also Published As

Publication number Publication date
TR199802624A3 (tr) 1999-10-21
HUP0102292A3 (en) 2003-12-29
MY128573A (en) 2007-02-28
SK286422B6 (sk) 2008-09-05
AU770818B2 (en) 2004-03-04
EG22250A (en) 2002-11-30
EP1042321A1 (en) 2000-10-11
US7368574B2 (en) 2008-05-06
EA200000656A1 (ru) 2000-12-25
JP2002508371A (ja) 2002-03-19
US20020133016A1 (en) 2002-09-19
TR200001793T2 (tr) 2000-10-23
CZ20002206A3 (cs) 2000-12-13
HUP0102292A2 (hu) 2002-05-29
OA11900A (en) 2006-04-10
AU2272299A (en) 1999-07-05
UA66821C2 (uk) 2004-06-15
RS50080B (sr) 2009-01-22
UY25309A1 (es) 1999-07-19
NO20003070D0 (no) 2000-06-15
CZ300081B6 (cs) 2009-01-28
AU2753802A (en) 2002-05-16
BG104606A (en) 2001-02-28
KR100549141B1 (ko) 2006-02-03
IL160847A0 (en) 2004-08-31
HRP20000404A2 (en) 2000-12-31
AR016161A1 (es) 2001-06-20
NZ504703A (en) 2002-12-20
NO20003070L (no) 2000-06-15
NO317255B1 (no) 2004-09-27
IL136425A0 (en) 2001-06-14
TR199802624A2 (xx) 1999-10-21
TW487709B (en) 2002-05-21
MA26581A1 (fr) 2004-12-20
YU36400A (sh) 2003-12-31
SK9182000A3 (en) 2000-12-11
BR9813598A (pt) 2000-10-10
GB9726563D0 (en) 1998-02-11
AR017211A1 (es) 2001-08-22
US20050288513A1 (en) 2005-12-29
PE20000125A1 (es) 2000-03-03
ZA9811504B (en) 2000-06-15
AP2000001829A0 (en) 2000-06-30
US20070037859A1 (en) 2007-02-15
CA2314967A1 (en) 1999-06-24
ID24714A (id) 2000-08-03
PL341213A1 (en) 2001-03-26
US20030139604A1 (en) 2003-07-24
SA99200200B1 (ar) 2006-11-11
KR20010033140A (ko) 2001-04-25
EA002833B1 (ru) 2002-10-31
BG64850B1 (bg) 2006-06-30
WO1999031093A1 (en) 1999-06-24
AP1363A (en) 2005-01-21
CN101318957A (zh) 2008-12-10
CN1285831A (zh) 2001-02-28
IL136425A (en) 2004-08-31
UY25306A1 (es) 2000-12-29
CN101318956A (zh) 2008-12-10
CO4990943A1 (es) 2000-12-26

Similar Documents

Publication Publication Date Title
MA26581A1 (fr) Forme hydratee nouvelle d'un derive de thiazolidine-dione, procede pour sa preparation et composition pharmaceutique la contenant
DZ2538A1 (fr) Tartrate d'un dipeptide substitué procédé pour sa préparation et compositions pharmaceutiques le contenant.
DZ2581A1 (fr) Dérivés d'acides aryloxyarylsulfonylaminohydroxamiques procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2666A1 (fr) Dérivés d'acide hydroxamique compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2074A1 (fr) Formulation nouvelle contenant de la paroxétine, et procédé pour sa préparation.
DZ2416A1 (fr) Dérivés d'acide arylsulfonylhydroxamique procédé pour leur préparation et compositions les contenant.
DZ2753A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant.
DZ2407A1 (fr) Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant
FR2531087B1 (fr) Nouvelle forme d'ester de cefuroxime, procede pour sa preparation et composition pharmaceutique la contenant
CY2537B1 (fr) Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2303A1 (fr) Dérivés d'indazole nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2550A1 (fr) Dérivés d'azétidinylpropylpipéridine procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2786771B1 (fr) Procede de stabilisation d'un macrolide poly-ene et composition pharmaceutique contenant un tel compose
FR11C0007I2 (fr) Composition pharmaceutique stabilisee a l'aide d'un agent de base
DZ1923A1 (fr) Sels d'un derivé d'indole anti-migraineux, son Procédé de production et composition pharmaceutique le contenant.
DZ2358A1 (fr) Amides inhibiteurs de sécrétion de apo b/mtp procédé pour leur préparation et compositions pharmaceutiques les contenant
MA26426A1 (fr) Procedes et intermediaires pour la preparation de b-lactames monocycliques nouveaux et pour compositions pharmaceutiques les contenant
DZ2699A1 (fr) Dérivés d'érythromycine nouveaux procédé et intermédiaires pour préparation et compositions pharmaceutiques les contenant.
DZ2680A1 (fr) Dérivé de thiazolidinedione nouveau procédé pour sa préparation et composition pharmaceutique le contenant.
DZ2681A1 (fr) Forme nouvelle d'hydrate de sel d'acide maléique de 5-Ä4-Ä2-(n-methyl-n(2-pyridyl)amino)ethoxyÜbenzylÜ-thiazololidine-2,4-dione et composition pharmaceutique la contenant.
DZ2046A1 (fr) Forme cristalline nouvelle du sel d'acide méthanesulfonique d'acide 7-Ä(1alpha,5alpha,6alphaÜ-6-amino-3-azabicycloÄ3.1.0Ühex-3-yl)-6-fluoro -1-(2,4-difluorophényl)-1,4 dihydro-4-oxo-1,8-naphtyridine-3-carboxylique anhydre, procédé pour sa préparationet composition pharmaceutique la contenant.
FR2701708B1 (fr) Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
DZ2624A1 (fr) Dérivés d'isoquinoléine nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.